Ï㽶ÊÓƵ

About Dr. Behr

Marcel BehrDr. Marcel A. Behr, MD, M.Sc., FRCPC

Ï㽶ÊÓƵ Health Centre
1001 boul Décarie
Glen Block E,ÌýOffice #E05.1808
Montréal, QC H4
A 3J1ÌýCanada
Phone: 514 934-1934 (42815)
±ð³¾²¹¾±±ô:Ìýmarcel.behr [at] mcgill.ca
Lab website:

Infectious Diseases: /infect-diseases/
MI4: /mi4/

McGill TB Centre website:Ìý/tb
IDIGH Program:ÌýÌý
Twitter:ÌýÌýÌý

Dr. BehrÌýis a clinician-scientist with appointments ofÌýFull Professor in the Department of Medicine and Associate member in the departments of Epidemiology and Biostatistics as well as Microbiology and Immunology.ÌýHe is the foundingÌýDirector of the McGill International TB Centre and led it fromÌý2012 to 2018. He was the Associate Program Leader of the Program at the Research Institute of the Ï㽶ÊÓƵ Health Centre from 2016 to 2023. In 2017 he became the co-Director theÌýMcGill Interdisciplinary Initiative in Infection and Immunity (MI4)Ìýand became itsÌýDirector in late 2021.ÌýHe is theÌýDirector of theÌýMcGill Infectious Diseases Division.

Dr. Behr trained at the University of Toronto, Queen’s, McGill and Stanford.Ìý His work has been recognized in Quebec (Chercheur National Award of the FRSQ), Canada (Joe Doupe Award of the Clinical Society for Clinical Investigation, Fellow of the Canadian Academy of Health Sciences and of the Royal Society of Canada) and beyond (Election to the American Society for Clinical Investigation and Fellow of the American Academy of Microbiology). ÌýDr. Behr’s lab uses bacterial genetics to study the epidemiology and pathogenesis of mycobacterial diseases.Ìý

Most significant contributions:

Research in the Behr lab that employs bacterial geneticÌýmethods to study the epidemiology andÌýpathogenesis of mycobacterial diseases. Our work has been cited ~ 25,000 times with an h-indexÌýof 80. Highlights include the following:

  1. Mycobacterium tuberculosis evolution. We used microarrays to define the micro-evolutionÌýof the M. tuberculosis complex (MTC) (Mostowy et al, JID, 2002) and M. bovis BCGÌývaccines (Mostowy et al, Vaccine, 2003). WeÌýthen described the macro-evolution of M.Ìýtuberculosis from non-tuberculous mycobacteriaÌý(Veyrier, BMC Evolutionary Biology,Ìý2009), such as M. kansasii (Wang, Genome Biology and Evolution, 2015).Ìý To reorient TBÌýresearch, we imputed the ancestor of the M. tuberculosis complex (called MTBC 0 ) and sharedÌýthis sequence through Tuberculist as the new ‘North Star’ for TB research (Harrison,ÌýMicrobial Genomics, 2024).
  2. Mycobacterium avium. Using multi-locus sequence analysis, we derived a phylogeny ofÌýM.Ìýavium, revealing a mix of environmental organisms and pathogenic clones (Turenne etÌýal,ÌýJ. Bacteriology, 2008). This enabled us to identify horizontal gene transferÌýevents thatÌýdefine the pathogen M. avium paratuberculosis (Alexander et al, J.ÌýBacteriology, 2009). OurÌýappreciation of the species was captured in aÌýcomprehensive review (Turenne et al, ClinÌýMicro Reviews, 2007) andÌýserved as the basis for editing two reference textbooks onÌýParatuberculosis (2010, 2020).
  3. NOD2 and mycobacterial infection. We showed that NOD2 mediates innate andÌýadaptiveÌýimmune responses to mycobacterial infection (Divangahi et al, J. Immunology,
    2008).ÌýThen, using a ‘genetics squared’ approach, we showed that NOD2-dependentÌýimmuneÌýrecognition is tuned to the modified mycobacterial peptidoglycan, where theÌýC2Ìýposition of muramic acid has an unusual N-glycolyl group instead of the typical N-acetylÌýmoiety (Coulombe et al, J. Exp Med, 2009). N-glycolyl MDP is now commercially availableÌýthrough InvivoGen as an immunologic reagent.
  4. Tuberculosis molecular epidemiology. Using bacterial genotyping, our group has evaluatedÌýTB transmission over space and time. We tracked TB within a village that suffered a TBÌýsurge (Lee et al, JID, 2015) and characterized the evolution of that founder strain (Lee et al,ÌýPNAS, 2015). We demonstrated the importance of reinfection after treatment in South AfricaÌý(Verver, Am J Resp Crit Care Med, 2005). Our work showed thatÌýM. orygis (notÌýM. bovis) isÌýthe cause of zoonotic TB in India (Duffy et al, Lancet Microbe, 2020), resulting in anÌýupdated WHO definition (). TheseÌýgenomicÌýepidemiologyÌýstudies,Ìýcomplemented by historic literature, reinforced the importance of fastÌýdisease after infection (Behr et al, BMJ, 2018; BMJ, 2019) and led to the WHO changing its guidance on the global burden of M. tuberculosis infection ().Ìý

    (updated JuneÌý2024)
Back to top